Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer

Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the front-line setting.